KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short-term Investments (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Short-term Investments data on record, last reported at $229.2 million in Q3 2025.

  • For Q3 2025, Short-term Investments rose 6.9% year-over-year to $229.2 million; the TTM value through Sep 2025 reached $229.2 million, up 6.9%, while the annual FY2024 figure was $211.0 million, 21.38% down from the prior year.
  • Short-term Investments reached $229.2 million in Q3 2025 per NKTR's latest filing, up from $132.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $887.2 million in Q1 2021 and bottomed at $132.9 million in Q2 2025.
  • Average Short-term Investments over 5 years is $425.0 million, with a median of $358.7 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: crashed 49.18% in 2022, then rose 6.9% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $708.7 million in 2021, then tumbled by 41.2% to $416.8 million in 2022, then crashed by 35.61% to $268.3 million in 2023, then fell by 21.38% to $211.0 million in 2024, then increased by 8.63% to $229.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $229.2 million in Q3 2025, $132.9 million in Q2 2025, and $179.7 million in Q1 2025.